Business Description
Curis Inc
NAICS : 325414
SIC : 2836
ISIN : US2312692005
Total Employee Number:
24Description
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 11.22 | |||||
Equity-to-Asset | 0.43 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -61.05 | |||||
Beneish M-Score | -4.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -30.9 | |||||
3-Year EBITDA Growth Rate | 39.1 | |||||
3-Year EPS without NRI Growth Rate | 39.8 | |||||
3-Year FCF Growth Rate | 43.9 | |||||
3-Year Book Growth Rate | -64.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 43.65 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 70.71 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.25 | |||||
9-Day RSI | 57.2 | |||||
14-Day RSI | 53.13 | |||||
6-1 Month Momentum % | -49.09 | |||||
12-1 Month Momentum % | -75.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.11 | |||||
Quick Ratio | 1.11 | |||||
Cash Ratio | 1 | |||||
Days Sales Outstanding | 150.63 | |||||
Days Payable | 61225.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -38.8 | |||||
Shareholder Yield % | -115.04 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 99.56 | |||||
Operating Margin % | -485.12 | |||||
Net Margin % | -299.66 | |||||
EBITDA Margin % | -484.41 | |||||
FCF Margin % | -411.09 | |||||
OCF Margin % | -411.09 | |||||
ROA % | -72.56 | |||||
ROIC % | -192.68 | |||||
3-Year ROIIC % | -378.3 | |||||
ROC (Joel Greenblatt) % | -1479.58 | |||||
ROCE % | -262.95 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.06 | |||||
PB Ratio | 1.64 | |||||
Price-to-Tangible-Book | 5.71 | |||||
EV-to-EBIT | -0.38 | |||||
EV-to-Forward-EBIT | -0.26 | |||||
EV-to-EBITDA | -0.38 | |||||
EV-to-Forward-EBITDA | -0.26 | |||||
EV-to-Revenue | 1.78 | |||||
EV-to-Forward-Revenue | 1.68 | |||||
EV-to-FCF | -0.23 | |||||
Price-to-GF-Value | 0.51 | |||||
Price-to-Median-PS-Value | 0.17 | |||||
Earnings Yield (Greenblatt) % | -266.52 | |||||
FCF Yield % | -120.43 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Curis Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6.061 | ||
| EPS (TTM) (€) | -1.038 | ||
| Beta | 1.5635 | ||
| 3-Year Sharpe Ratio | -1.44 | ||
| 3-Year Sortino Ratio | -1.55 | ||
| Volatility % | 60.77 | ||
| 14-Day RSI | 53.13 | ||
| 14-Day ATR (€) | 0.039053 | ||
| 20-Day SMA (€) | 0.35745 | ||
| 12-1 Month Momentum % | -75.65 | ||
| 52-Week Range (€) | 0.173 - 1.94 | ||
| Shares Outstanding (Mil) | 38.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Curis Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Curis Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 129 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 16:00 | In 129 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 08:30 | In 36 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 08:00 | In 36 days | ||
| General meeting for 2025 | 2026-05-19 11:00 | 0.42 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 16:30 | 0.47 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 0.47 (+0.00%) | ||
| Annual report for 2025 | 2026-03-24 | 0.65 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-19 16:30 | 0.78 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 16:00 | 0.78 (+0.00%) |
Show
Entries
Curis Inc Frequently Asked Questions
What is Curis Inc(FRA:CUS0)'s stock price today?
The current price of FRA:CUS0 is €0.40. The 52 week high of FRA:CUS0 is €1.94 and 52 week low is €0.17.
When is next earnings date of Curis Inc(FRA:CUS0)?
The next earnings date of Curis Inc(FRA:CUS0) is 2026-08-05 Est..
Does Curis Inc(FRA:CUS0) pay dividends? If so, how much?
Curis Inc(FRA:CUS0) does not pay dividend.
Press Release
Articles on Curis Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers